The effect of weight loss on health‐related quality of life: systematic review and meta‐analysis of randomized trials

Warkentin, Lindsey M.; Das, Debraj; Majumdar, Sumit R.; Johnson, Jeffrey; Padwal, Raj

doi:10.1111/obr.12113

Cited by 168 publications

(204 citation statements)

References 70 publications

Supporting

Mentioning

168

Contrasting

Unclassified

Order By: Relevance

“…A recent systematic review of HRQoL outcomes in 53 randomized trials for weight loss interventions included only four bariatric surgery studies, with follow-ups ranging between 52 and 104 weeks [10] . Thus, we aimed to conduct a systematic review of prospective studies reporting HRQoL data at least five years after bariatric surgery.…”

Section: Introductionmentioning

confidence: 99%

Health-related quality of life after bariatric surgery: a systematic review of prospective long-term studies

Andersen

Aasprang²,

Karlsen

et al. 2015

Surgery for Obesity and Related Diseases

136

103

View full text Add to dashboard Cite

Impaired health-related quality of life (HRQoL) is common in bariatric surgery candidates and is often one of the motivating factors for seeking bariatric surgery. Although many studies have reported changes in HRQoL after bariatric surgery, few are long-term prospective studies and no systematic review has been conducted. A systematic database search identified studies reporting HRQoL preoperatively and ≥ 5 years after bariatric surgery. Change in HRQoL over time was the outcome variable, divided into primary and secondary outcomes. Seven prospective cohort studies met the inclusion criteria. Eight HRQoL measures and six surgical methods were identified. Longterm follow-up time ranged from 5-10 years, sample sizes from 44 to 655 patients, and follow-up rates from 61 to 92%. None of the seven studies were randomized controlled trails and only two studies used control groups. Six out of seven studies showed statistically significant improvements in all of the primary outcomes, while one study showed statistically significant improvements in one of two primary outcomes. Of the statistically significant HRQoL improvements, 92 percent were clinically meaningful. Peak improvements in primary HRQoL outcomes were typically observed during the first years of follow-up, followed by a gradual decline that seemed to stabilize five years postoperatively. Long-term HRQoL scores typically remained improved relative to preoperative scores but were somewhat below population norm scores. In conclusion, while bariatric surgery candidates reported impaired HRQoL pre-surgically, their HRQoL improved considerably after bariatric surgery and much of the initial HRQoL improvements were maintained over the long term.

show abstract

Section: Introductionmentioning

confidence: 99%

Health-related quality of life after bariatric surgery: a systematic review of prospective long-term studies

Andersen

Aasprang²,

Karlsen

et al. 2015

Surgery for Obesity and Related Diseases

136

103

View full text Add to dashboard Cite

show abstract

“…1,2 Weight loss of 5 to 10% has been shown to reduce complications related to obesity and improve quality of life [3][4][5][6][7] ; however, weight loss is difficult to maintain with lifestyle intervention alone. 8 Liraglutide, a glucagon-like peptide-1 analogue with 97% homology to human glucagon-like peptide-1, is approved for the treatment of type 2 diabetes at doses up to 1.8 mg once daily.…”

mentioning

confidence: 99%

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

et al. 2015

View full text Add to dashboard Cite

BACKGROUNDObesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagonlike peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODSWe conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight. RESULTSAt baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes. At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of −5.6 kg; 95% confidence interval, −6.0 to −5.1; P<0.001, with last-observation-carried-forward imputation). A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001). The most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea. Serious events occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the placebo group. CONCLUSIONSIn this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control. (Funded by Novo Nordisk; SCALE Obesity and Prediabetes NN8022-1839 ClinicalTrials.gov number, NCT01272219.) a bs tr ac t

show abstract

“…Obesity induces systemic oxidative stress 39 and alters the 6MWD 40 and/or QOL. 41 As in the present study, the non-COPD group, compared with the COPD group, includes a significantly higher percentage of obese smokers; this could For the non-COPD group, n ϭ 16; for the COPD group, n ϭ 16. F ENO ϭ fractional exhaled nitric oxide MDA ϭ malondialdehyde PSH ϭ protein sulfhydryl GSH ϭ glutathione ⌬ ϭ 6-min walk test (end Ϫ resting) values QOL ϭ quality of life be a serious limitation (see Table 1).…”

Section: Study Limitationsmentioning

confidence: 46%

Incapacity, Handicap, and Oxidative Stress Markers of Male Smokers With and Without COPD

2016

View full text Add to dashboard Cite

The effect of weight loss on health‐related quality of life: systematic review and meta‐analysis of randomized trials

Cited by 168 publications

References 70 publications

Health-related quality of life after bariatric surgery: a systematic review of prospective long-term studies

Health-related quality of life after bariatric surgery: a systematic review of prospective long-term studies

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Incapacity, Handicap, and Oxidative Stress Markers of Male Smokers With and Without COPD

Contact Info

Product

Resources

About